202 related articles for article (PubMed ID: 38017575)
1. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
Bunnik EM; Aarts N
BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
[TBL] [Abstract][Full Text] [Related]
4. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.
Maeda H; Uchida M; Kusano M; Tsukamoto K; Yamanoi M
Clin Pharmacol Ther; 2022 Oct; 112(4):817-823. PubMed ID: 35569010
[TBL] [Abstract][Full Text] [Related]
6. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
[TBL] [Abstract][Full Text] [Related]
7. Compassionate Drug Use - Time Arising for a New Law in Bulgaria in the Era of COVID-19.
Dzhafer N; Papathanasiou JV
Folia Med (Plovdiv); 2020 Sep; 62(3):592-596. PubMed ID: 33009760
[TBL] [Abstract][Full Text] [Related]
8. [Which efficacy trials for drugs for rare diseases?].
Traversa G; Trotta F
Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
[No Abstract] [Full Text] [Related]
9. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
11. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
McKee AE; Markon AO; Chan-Tack KM; Lurie P
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
[TBL] [Abstract][Full Text] [Related]
12. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
Goldman SA
Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
[TBL] [Abstract][Full Text] [Related]
13. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
14. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
[TBL] [Abstract][Full Text] [Related]
15. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
16. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
Speers MA
Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.
Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H
JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206
[TBL] [Abstract][Full Text] [Related]
20. Expanded access to investigational drugs in psychiatry: A systematic review.
Vermeulen SF; Polak TB; Bunnik EM
Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
